Advanced Search: Diffuse Large B-Cell

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201912027

Phase I-II Trial of Venetoclax in Combination with R-ICE (V-RICE) Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

202003073

SGN35-31 - A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

202001014

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination with Rituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia

202001157

A MULTICENTER, OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, EFFICACY,TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF RO7082859 AS A SINGLE AGENT AND IN COMBINATION WITH OBINUTUZUMAB ADMINISTERED AFTER A FIXED, SINGLE DOSE PRE-TREATMENT OF,OBINUTUZUMAB (GAZYVA/GAZYVARO) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

201505024

An Open-Label, Multicenter, Phase I/II trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia

202008005

SRP001: A Phase 1 Study of FSI-189 as Monotherapy and in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

201608007

A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients with Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype

201612005

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma